
Day 0
Days 1–8
Days 9–71
Day 100
Extended follow-up (up to 6 mo)
Screening
Randomization
PF-06439535
n = 33
Bevacizumab-EU
n = 35
Bevacizumab-US
n = 33
Confined to unit
Outpatient visits
Day 1
Study drug administration
Day 8
Discharge from unit
Visit days
15, 22, 29, 43, 57, 64, 71, 100
Primary PK assessment
ADA assessment
Day 1 2 3 5 8 15 22 29 43 57 64 71 100
Hour 0[a], 1.5,4 24 48 96 168 336[a] 504 672[a] 1008 1344[a] 1512 1680[a] 2376[a]